Patent ID: 9709573
Date: 2017-07-18
CPC Classifications: G01N,H01J

Claim:
1. A method for detecting citrullinated brain injury biomarker proteins in a sample from a patient, the method comprising: detecting in a patient sample citrullinated arginine residues in citrullinated brain injury biomarker protein neurogranin (NRGN) and in one or more citrullinated brain injury biomarker proteins selected from the group consisting of tubulin beta-4B chain, tubulin alpha-1B chain, CNPase, PPIA, Septin-7, Elongation factor1-alpha2, TPPP, TPPP3, Ermin Isoform 2, NDRG2Isoform 2, astrotactin 1 (ASTN1), brain angiogenesis inhibitor 3 (BAI3), carnosine dipeptidase 1 (CNDP1), ERMIN, glial fibrillary acidic protein (GFAP), glutamate receptor metabotropic 3 (GRM3), kelch-like protein 32 (KLH32), melanoma antigen family E,2 (MAGE2), myelin basic protein (MBP), neuregulin 3 (NRG3), oligodendrocyte myelin glycoprotein (OMG), solute carrier family 39 (zinc transporter), reticulon 1 (RTN1), MT3, and peptidylarginine deiminase (types 1-4 and 6) (PAD) by contacting the citrullinated arginine residues in the citrullinated brain injury biomarker proteins with an antibody that binds to said citrullinated arginine residues and detecting binding of the antibody to the residues or by detecting the citrullinated arginine residues using mass spectrometry, thereby detecting citrullinated brain injury biomarker proteins in the patient's sample.